Full name
The REIMAGINE Study: A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma
NCT Number
NCT06041386
Geography
US
Non-US
Locations
Belgium, Canada, France, Germany, Italy, Japan, Poland, Spain, United States
Primary Endpoints
Percentage (%) of Participants Achieving 4-Component Clinical Remission* at month 12
*4-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an Asthma Control Test (ACT) (d) No clinically significant deterioration of lung function.
Order
3
Disease
Version
Phase
4
Status
Active, not recruiting